Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jul;30(1):49–54. doi: 10.1111/j.1365-2125.1990.tb03742.x

Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.

J J Series 1, A Gaw 1, C Kilday 1, D K Bedford 1, A R Lorimer 1, C J Packard 1, J Shepherd 1
PMCID: PMC1368274  PMID: 2390432

Abstract

1. This study was designed to examine the effects of acipimox 250 mg three times daily and cholestyramine 4 g three times daily on plasma lipids and lipoproteins in 28 hypercholesterolaemic individuals in a prospective double-blind placebo controlled parallel group fashion. 2. Combined treatment with the two agents produced a mean reduction of 27% in plasma total cholesterol and a 32% fall in LDL cholesterol. Plasma triglyceride was reduced by 13% due to a 38% decrement in VLDL cholesterol. 3. In comparison treatment with cholestyramine alone resulted in a 12% fall in plasma cholesterol and a 15% fall in LDL cholesterol. In this group triglycerides and VLDL showed no significant change. 4. Studies of HDL subfraction mass showed that the addition of acipimox to resin therapy produced a mean increment of 45% in HDL2. 5. These results demonstrate the effectiveness of such a well tolerated low dosage combination therapy.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelin B., Björkhem I., Einarsson K. Influence of bile acids on the soluble phosphatidic acid phosphates in rat liver. Biochem Biophys Res Commun. 1981 May 29;100(2):606–612. doi: 10.1016/s0006-291x(81)80219-7. [DOI] [PubMed] [Google Scholar]
  2. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  3. Brown M. S., Goldstein J. L. Familial hypercholesterolemia: genetic, biochemical and pathophysiologic considerations. Adv Intern Med. 1975;20:273–296. [PubMed] [Google Scholar]
  4. Carlson L. A., Orö L., Ostman J. Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia during the first week of treatment. J Atheroscler Res. 1968 Jul-Aug;8(4):667–677. doi: 10.1016/s0368-1319(68)80025-0. [DOI] [PubMed] [Google Scholar]
  5. Crepaldi G., Avogaro P., Descovich G. C., Di Perri T., Postiglione A., Sirtori C. R., Strano A., Ventura S., Musatti L. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. Atherosclerosis. 1988 Mar;70(1-2):115–121. doi: 10.1016/0021-9150(88)90105-0. [DOI] [PubMed] [Google Scholar]
  6. Crepaldi G., Avogaro P., Descovich G. C., Di Perri T., Postiglione A., Sirtori C. R., Strano A., Ventura S., Musatti L. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. Atherosclerosis. 1988 Mar;70(1-2):115–121. doi: 10.1016/0021-9150(88)90105-0. [DOI] [PubMed] [Google Scholar]
  7. Goldfarb S., Pitot H. C. Stimulatory effect of dietary lipid and cholestyramine on hepatic HMG CoA reductase. J Lipid Res. 1972 Nov;13(6):797–801. [PubMed] [Google Scholar]
  8. Grundy S. M., Goodman D. W., Rifkind B. M., Cleeman J. I. The place of HDL in cholesterol management. A perspective from the National Cholesterol Educational Program. Arch Intern Med. 1989 Mar;149(3):505–510. [PubMed] [Google Scholar]
  9. Grundy S. M., Goodman D. W., Rifkind B. M., Cleeman J. I. The place of HDL in cholesterol management. A perspective from the National Cholesterol Educational Program. Arch Intern Med. 1989 Mar;149(3):505–510. [PubMed] [Google Scholar]
  10. Kane J. P., Malloy M. J., Tun P., Phillips N. R., Freedman D. D., Williams M. L., Rowe J. S., Havel R. J. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 1981 Jan 29;304(5):251–258. doi: 10.1056/NEJM198101293040502. [DOI] [PubMed] [Google Scholar]
  11. Kane J. P., Malloy M. J., Tun P., Phillips N. R., Freedman D. D., Williams M. L., Rowe J. S., Havel R. J. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 1981 Jan 29;304(5):251–258. doi: 10.1056/NEJM198101293040502. [DOI] [PubMed] [Google Scholar]
  12. Kannel W. B., Castelli W. P., Gordon T., McNamara P. M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 Jan;74(1):1–12. doi: 10.7326/0003-4819-74-1-1. [DOI] [PubMed] [Google Scholar]
  13. Kannel W. B., Castelli W. P., Gordon T., McNamara P. M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 Jan;74(1):1–12. doi: 10.7326/0003-4819-74-1-1. [DOI] [PubMed] [Google Scholar]
  14. Martin M. J., Hulley S. B., Browner W. S., Kuller L. H., Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986 Oct 25;2(8513):933–936. doi: 10.1016/s0140-6736(86)90597-0. [DOI] [PubMed] [Google Scholar]
  15. Martin M. J., Hulley S. B., Browner W. S., Kuller L. H., Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986 Oct 25;2(8513):933–936. doi: 10.1016/s0140-6736(86)90597-0. [DOI] [PubMed] [Google Scholar]
  16. Packard C. J., Stewart J. M., Morgan H. G., Lorimer A. R., Shepherd J. Combined drug therapy for familial hypercholesterolemia. Artery. 1980;7(4):281–289. [PubMed] [Google Scholar]
  17. Shepherd J., Caine E. A., Bedford D. K., Packard C. J. Ultracentrifugal subfractionation of high-density lipoprotein. Analyst. 1984 Mar;109(3):347–351. doi: 10.1039/an9840900347. [DOI] [PubMed] [Google Scholar]
  18. Shepherd J., Caine E. A., Bedford D. K., Packard C. J. Ultracentrifugal subfractionation of high-density lipoprotein. Analyst. 1984 Mar;109(3):347–351. doi: 10.1039/an9840900347. [DOI] [PubMed] [Google Scholar]
  19. Shepherd J., Packard C. J., Patsch J. R., Gotto A. M., Jr, Taunton O. D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979 May;63(5):858–867. doi: 10.1172/JCI109385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Shepherd J., Packard C. J., Patsch J. R., Gotto A. M., Jr, Taunton O. D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979 May;63(5):858–867. doi: 10.1172/JCI109385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. de Paolis C., Farina R., Pianezzola E., Valzelli G., Celotti F., Pontiroli A. E. Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug. Br J Clin Pharmacol. 1986 Oct;22(4):496–497. doi: 10.1111/j.1365-2125.1986.tb02926.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. de Paolis C., Farina R., Pianezzola E., Valzelli G., Celotti F., Pontiroli A. E. Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug. Br J Clin Pharmacol. 1986 Oct;22(4):496–497. doi: 10.1111/j.1365-2125.1986.tb02926.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES